Current optimal chemotherapy for advanced urothelial cancer. Issue 1 (January 2008)

• Record Type: Journal Article
• Authors: Sonpavde, Guru; Galsky, Matthew D; Hutson, Thomas E
• Is Part Of: Expert review of anticancer therapy. Volume 8:Issue 1(2008)
• Page Start: 51
• Page End: 61
• Publication Date: 2008-01
• Subjects: advanced urothelial cancer -- chemotherapy -- transitional cell cercinoma -- urothelial cancer; Cancer -- Treatment -- Periodicals; 616.99406
• DOI: 10.1586/14737140.8.1.51
• Languages: English
• ISSNs: 1473-7140

Abstract

Conventional frontline cisplatin-based combination chemotherapy with gemcitabine and cisplatin, or traditional or dose-dense methotrexate, vinblastine, doxorubicin and cisplatin, yields high response rates but few durable remissions for advanced urothelial cancer. Salvage therapy is generally disappointing with few responses. A significant proportion of patients exhibit renal dysfunction, entailing carboplatin-based regimens that appear inferior to cisplatin-based regimens, which warrants a special focus In this population. The profusion of novel biologic agents offers the promise of improved outcomes. A multidisciplinary approach is necessary to make therapeutic advances.